Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) ...
Pharmabiz22h
Relief Therapeutics to receive European patent covering RLF-TD011 for epidermolysis bullosa wound treatment
Relief Therapeutics to receive European patent covering RLF-TD011 for epidermolysis bullosa wound treatment: Geneva Tuesday, October 22, 2024, 13:00 Hrs [IST] Relief Therapeutics ...
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa ...
PharmiWeb15d
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
The study was designed to evaluate the effects of RLF-TD011 on microbiome diversity in wounds of patients with dystrophic and junctional EB. Microbiome analysis showed a statistically significant ...
Morningstar15d
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
The study was designed to evaluate the effects of RLF-TD011 on microbiome diversity in wounds of patients with dystrophic and junctional EB. Microbiome analysis showed a statistically significant ...
Seeking Alpha5d
RLFTY Relief Therapeutics Holding SA
In addition, the company also develops HCU GOLIKE, which is in Phase I clinical trial for the treatment of Homocystinuria; and RLF-TD011, a hypochlorous acid topical sprayable solution ...
Le Lézard15d
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to ...